Plasmodium lactate dehydrogenase (pLDH) is a strong target antigen for the determination of infection with Plasmodium species specifically. However, a more effective antibody is needed because of the low sensitivity of the current antibody in many immunological diagnostic assays. In this study, recombinant Plasmodium vivax LDH (PvLDH) was experimentally constructed and expressed as a native antigen to develop an effective P. vivax-specific monoclonal antibody (mAb). Two mAbs (2CF5 and 1G10) were tested using ELISA and immunofluorescence assays (IFA), as both demonstrated reactivity against pLDH antigen. Of the 2 antibodies, 2CF5 was not able to detect P. falciparum, suggesting that it might possess P. vivax-specificity. The detection limit for a pair of 2 mAbs-linked sandwich ELISA was 31.3 ng/ml of the recombinant antigen. The P. vivax-specific performance of mAbs-linked ELISA was confirmed by in vitro-cultured P. falciparum and P. vivax-infected patient blood samples. In conclusion, the 2 new antibodies possessed the potential to detect P. vivax and will be useful in immunoassay.
Citations
Citations to this article as recorded by
Diagnostic Methods for Non-Falciparum Malaria Alba Marina Gimenez, Rodolfo F. Marques, Matías Regiart, Daniel Youssef Bargieri Frontiers in Cellular and Infection Microbiology.2021;[Epub] CrossRef
Plasmodium falciparum Parasitemia and Band Sensitivity of the SD Bioline Malaria Ag P.f/Pan Rapid Diagnostic Test in Madagascar Rajeev K. Mehlotra, Rosalind E. Howes, Estee Y. Cramer, Riley E. Tedrow, Tovonahary A. Rakotomanga, Stéphanie Ramboarina, Arsène C. Ratsimbasoa, Peter A. Zimmerman
The American Journal of Tropical Medicine and Hygiene.2019; 100(5): 1196. CrossRef